Rituximab
From Ganfyd
rINN: Rituximab
Pharmacological Information
Pharmacology Images
File:RituximabMolecule.png
Rituximab Molecule
Web information on Rituximab
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Medpedia on Rituximab (Less technical, good quality control)
Wikipedia on Rituximab (Less technical, ? quality control)
Contents |
Introduction
Rituximab (MabThera®) is a monoclonal antibody directed against CD20, a cell surface receptor found on B cells. Used in treatment of non-Hodgkin's lymphoma in patients who are not fit enough for chemotherapy or have advanced disease.
Clinical Use
Indications
- Relapsed/refractory follicular lymphoma responding to induction therapy with chemotherapy
- Stage III-IV follicular lymphoma in combination with chemotherapy
- CD20+ive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy
May be used as an immunosuppresant, e.g. in transplant rejection, certain nephropathies and auto-immune disorders suchas antiphospholipid syndrome.
Administration
IV
Clinical Issues
Contra-indications
Cautions and Interactions
Side effects
Special advice
Pharmacology
References
This article is a work in progress. Please feel free to contribute to it.
